Prospectus

Isofol publishes prospectus in connection with the company’s rights issue

By

GOTHENBURG, Sweden, 17 June 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (”Isofol” or the “Company”) announced on 12 May 2025 that it had resolved to carry out a rights issue of units, comprising shares and warrants, with preferential rights for the Company’s existing shareholders (the “Rights Issue”), amounting […]

Isofol publishes prospectus in connection with the company’s rights issue Read More »

Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm

By

GOTHENBURG, Sweden, October 18, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol” or the “Company”), announced today that the prospectus prepared by the Company in connection with the listing on Nasdaq Stockholm has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen). The prospectus contains updated financial

Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm Read More »

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million

By

GOTHENBURG, Sweden, May 25, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the “Company”) Board of Directors resolved on May 18, 2021, on an issue of shares of a maximum of 62,524,474 shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”). If the Rights Issue

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million Read More »

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million

By

GOTHENBURG, Sweden, May 14, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”) Board of Directors resolved on May 7, 2020, on a fully guaranteed new share issue of a maximum of 42,739,736 shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”). Through the

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million Read More »

Scroll to Top